Rituxan copycat passes first pivotal test for Amgen, Allergan; Ironwood and biotech spinout name new boards

→ Amgen and their partners at Allergan say their pivotal study of a Rituxan knockoff came through with positive PK results for patients with rheumatoid arthritis. They’re also running a separate pivotal for non-Hodgkin’s lymphoma which will go into their regulatory filing for an approval.

→ New boards have been established for Ironwood and its biotech spinout Cyclerion. Industry vet Julie McHugh will chair the Ironwood board while Cyclerion named Marsha Fanucci — an ex-Genzyme/Millennium exec — to the head of their new board.

→ AIT Therapeutics has licensed commercial rights for its cylinder free nitric oxide generator and phasic-flow delivery system in the US and China to Circassia Pharmaceuticals. It’s a $32.5 million deal.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,900+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->